Skinosive is a science-based biotechnology company specializing in dermocosmetics, founded by Truffle Capital, which is developing a proprietary technology platform called “bioadhesion” that could be applied to several use (cosmetic, medical…)

Skin cancer is the leading cause of cancer among Caucasians. The best means of prevention remains sun protection, but this has two major limitations: its effectiveness, as it must be reapplied every two hours, and the issue of skin penetration.

Skinosive is the only company developing an innovation based on a new generation of safe, long-acting bioadhesive filters. This breakthrough represents a radical innovation in sun protection and skin cancer prevention.

Skionosive’s mission is to revolutionize sun protection through a unique biotechnology platform. Molecules develop will stick to the skin, do not need to reapply every 2 hours, allow an extended duration of effectiveness up to 8 hours and does not penetrate the skin.

Their proprietary bio-adhesive technology is designed to set a new standard in sun protection. Their approach involves developing new UV filters that combine a bio-adhesive complex with already-approved UV filters, enabling them to anchor themselves to the stratum corneum, thereby improving durability with proven efficacy for up to 8 hours and limiting skin penetration.

The company is based in France, with headquarters in Paris and laboratories in Marseille.